|
Up a level |
Denkert, C; Kronenwett, R; Schlake, W; Bohmann, K; Penzel, R; Weber, K E; Höfler, H; Lehmann, U; Schirmacher, P; Specht, K; Rudas, M; Kreipe, H H; Schraml, P; Schlake, G; Bago-Horvath, Z; Tiecke, F; Varga, Z; Moch, H; Schmidt, M; Prinzler, J; Kerjaschki, D; Sinn, B V; Müller, B M; Filipits, M; Petry, C; Dietel, M (2012). Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv, 460(3):251-259.
Noske, A; Loibl, S; Darb-Esfahani, S; Roller, M; Kronenwett, R; Müller, B M; Steffen, J; von Toerne, C; Wirtz, R; Baumann, I; Hoffmann, G; Heinrich, G; Grasshoff, S T; Ulmer, H U; Denkert, C; von Minckwitz, G (2011). Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Research and Treatment, 126(1):109-117.
Lehmann, A; Denkert, C; Budczies, J; Buckendahl, A C; Darb-Esfahani, S; Noske, A; Müller, B M; Bahra, M; Neuhaus, P; Dietel, M; Kristiansen, G; Weichert, W (2009). High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer, 9:395.